Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Ginkgo Bioworks

Synthetic biology startups are breaking into the multi-billion-dollar market for industrial enzymes that power reactions for pharmaceutical, chemical, textile, food, and other companies.

How? Synthetic biologists take component DNA sequences that form different enzymes and patch them together to create a biological code. This code can produce new pathways for enzymes to work together or for organisms to produce them. These are then handed to commercial partners who manufacture them in bulk.

Tobias Erb from the Max Planck Institute for Terrestrial Microbiology is trying to create new pathways to capture and convert CO2 — last year they designed one that is more efficient at this than photosynthesis. He tells Axios:

"The power of synthetic biology lies in the fact that nowadays we are able to order and test synthetic DNA in a standardized fashion and for very little money, which allows us to test many different enzymes and enzymes variants. The problem is that the testing itself now creates a bottleneck."

What they're after: Every plant, animal, and microbe functions because of enzymes. They catalyze the digestion of food, prevent blood from clotting, and help cells communicate with one another. Wine, bread, cheese, medicines, contact lens solution, laundry detergent, and a long list of other things we enjoy, dislike, and otherwise rely on work because of enzymes. They are, in other words, vital, useful, and lucrative (industrial enzymes are a nearly $5 billion business).

Tens of thousands of enzymes have been isolated and described but the challenge in finding new reactions is two-fold:

  1. First, enzymes have to be identified. The relatively cheap cost of genetic sequencing is allowing companies to build vast libraries of genetic sequences for enzymes found in microorganisms that work in extreme environments — high or low temperatures, acidic, or basic solutions — similar to those in industrial processes.
  2. But, enzymes have been honed through evolution to perform specific functions in a particular organism, and it can be difficult to use them beyond nature's intent.

How it's done: For nearly 30 years, engineers have used directed evolution, a technique pioneered by Caltech's Frances Arnold, to modify enzymes for industrial use.

  • It involves introducing random mutations into a gene to produce new versions of the protein it encodes, which are then screened for desired properties.
  • It's been used to make new chemistries altogether: Arnold's team created an enzyme that can form carbon-silicon bonds that are rare in nature.
  • The powerful approach has improved and optimized detergents, biofuels, the synthesis of drugs and a host of other products and processes, but it can't solve every problem and it can be slow.

This is where startups see an opening.

Some key players: For their first foray into enzymes, Ginkgo Bioworks is partnering with food ingredient company Kerry and Swissaustral, which develops extremophilic enzymes for scientific research, personal care, and chemicals. The team is engineering strains of microorganisms to produce industrial enzymes at scale. They plan to later screen proprietary collections of enzymes (like temperature-resilient catalases that protect cells from oxidative damage by breaking down hydrogen peroxide) and attempt to engineer them for food and textile industry applications.

Ginkgo's automated "foundry" speeds up the time to develop the strains of microorganisms for producing an enzyme. San Francisco-based Zymergen is also using machine learning and robotics to manipulate microbes en masse into making materials.

Seattle-based Arzeda takes a different tack: They start with what they need an enzyme to do — cut this, add that — and work backwards, using computer algorithms to design enzymes and pathways with the function they want. They then use Arnold's method of directed evolution to hone those proteins. For INVISTA, Arzeda created a way to synthesize nylon precursors using sugar as the starting point.

"We design proteins that don't exist in nature and expand the repertoire of natural enzymes in order to make new reactions for industrial applications. The possibilities are truly limitless to expand on what nature has evolved and create new function at the protein level," says Arzeda CEO Alex Zanghellini.

DuPont, Novozyme, Cargill, BASF and other heavy-hitters in the chemicals industry that manufacture enzymes — and use directed evolution themselves — are potential customers for the startups. But so far, industries have been conservative in adopting synthetic biology, in part due to regulatory unknowns and concerns about public acceptance.

"I don't think we'll be limited by the complexity of biology. It will be more limited by the pace at which we can discover commercially and socially relevant jobs and problems we need done. That is the rate-limiting step," says Brian Brazeau of Ginkgo Bioworks.

Go deeper

Updated 35 mins ago - Politics & Policy

Top Pentagon officials contradict Biden on Afghanistan advice

Photo: Carolone Brehman/Pool/AFP via Getty Images

Top military leaders confirmed in a Senate hearing Tuesday they recommended earlier this year that the U.S. keep 2,500 troops in Afghanistan, and that they believed withdrawing those forces would lead to the collapse of the Afghan military.

Why it matters: Biden denied last month that his top military advisers wanted troops to remain in Afghanistan, telling ABC's George Stephanopoulos: "No one said that to me that I can recall."

Poll: Latinas more likely to open their own businesses, despite pandemic setbacks

Janie Isidoro, owner of My Corazon, a Chicano business in downtown Hanford, Calif. Photo: Al Seib/Los Angeles Times via Getty Images

Latinas in the U.S. are more likely to own, or plan to open, their own businesses than non-Hispanic women, despite the pandemic’s disproportionate burden, a recent poll found.

Why it matters: The survey, conducted by Telemundo, the Latino Victory Foundation and Hispanics Organized for Political Equality, suggests Latinas can be a driver of growth for the U.S. even though they have faced greater COVID-19-related setbacks.

Warren opposes Fed chair Powell's renomination, calls him a "dangerous man"

Sen. Elizabeth Warren speaks during a hearing before Senate Armed Services Committee on Sept. 28. Photo: Alex Wong/Getty Images

Sen. Elizabeth Warren (D-Mass.) questioned Federal Reserve Chair Jerome Powell's record on financial regulation during a hearing Tuesday, calling him a "dangerous man" and saying that she would not support his renomination for a second term.

Driving the news: While the Fed chair’s term expires in early 2022, President Biden is expected to make a decision this fall on whether to reappoint Powell or nominate another candidate.